Claire E. Dearden, MD, Highlights the Pharmacotherapeutic Strategies for the Management of B- and T-cell PLL

Article

Claire E. Dearden, MD, Consultant Hematologist, Head of CLL Clinic, Royal Marsden Hospital, London, UK, highlights the pharmacotherapeutic strategies for the management of B- and T-cell PLL, noting the clinical outcomes associated with the diseases, and briefly touches on the future of PLL therapy.

Claire E. Dearden, MD, Consultant Hematologist, Head of CLL Clinic, Royal Marsden Hospital, London, UK, highlights the pharmacotherapeutic strategies for the management of B- and T-cell PLL, noting the clinical outcomes associated with the diseases, and briefly touches on the future of PLL therapy.

This video was taken on Saturday, December 8, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.

Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Related Content
FDA Approves Sanofi’s siRNA Therapy Fitusiran for the Treatment of Hemophilia A and B

FDA Approves Sanofi’s siRNA Therapy Fitusiran for the Treatment of Hemophilia A and B

Noah Stansfield
March 31st 2025
Article

The product is marketed under the name Qfitlia.

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

Natalie Goedeker, CPNP, the codirector of pediatric neuromuscular clinical research at Washington University in St. Louis

Handling Neuromuscular Gene Therapy at Real-World Sites

Natalie Goedeker, CPNP;Noah Stansfield
March 30th 2025
Article

Natalie Goedeker, CPNP, the codirector of pediatric neuromuscular clinical research at Washington University in St. Louis, discussed the session she chaired at MDA’s 2025 conference.

ImmunoLogic

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
January 31st 2025
Podcast

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – March 28, 2025

Noah Stansfield
March 28th 2025
Article

Review top news and interview highlights from the week ending March 28, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Noah Stansfield
March 26th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

© 2025 MJH Life Sciences

All rights reserved.